Kantonsspital Baden AG
- Address
- Im Ergel 1
Sponsor Overview
Specializations
Type II diabetes mellitus
Clinical research at Kantonsspital Baden AG includes studies in type II diabetes mellitus, with attention to patients whose glycaemic control remains insufficient despite standard antidiabetic treatment. The sponsor’s work in this area reflects a focus on improving metabolic control and reducing the burden of diabetes-related complications.
- HbA1c reduction
- Anti-diabetic therapy
- Diabetes-related complications
The diabetes portfolio is centred on therapeutic strategies that support better long-term blood glucose management in adult patients.
Inflammatory and autoimmune disorders
The sponsor also funds research in inflammatory and autoimmune disorders, with clinical interest in treatment approaches for patients receiving systemic anti-inflammatory therapy. This area includes evaluation of treatment adjustment strategies in disorders where immune-mediated inflammation is a major clinical concern.
- Systemic glucocorticoid treatment
- Inflammatory disorders
- Autoimmune disease management
Research in this field is directed toward optimising care for conditions requiring careful control of immune-mediated inflammation.
Glucocorticoid therapy management
Another therapeutic domain of interest is the management of glucocorticoid treatment in patients with inflammatory conditions. The sponsor’s clinical activity includes questions around treatment discontinuation and tapering strategies, with relevance to routine care in steroid-treated patients.
- Systemic corticosteroids
- Treatment tapering
- Therapy discontinuation
This area links endocrine and immunological considerations in the management of chronic inflammatory disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Randomized Controlled Trial on the Efficacy of Prednisone Tapering Versus Abrupt Discontinuation in Patients with Inflammatory or Autoimmune Disorders |  Germany | Recruiting |
| Randomized, Double-Blind, Placebo-Controlled Study of Dapansutrile for Glycemic Control in Type 2 Diabetes Mellitus Patients on Standard Therapy |  Belgium France Germany | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
- 2.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
5 centres- Address
- Avenue De L'Hopital 1, 4000 Liège
- Address
- Auf'm Hennekamp 65, Nordrhein-Westfalen, 40225 Düsseldorf
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Straubmuehlweg 2a, Grombuehl, 97078 Würzburg
- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kantonsspital Baden AG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.